Full-Time

Operational Strategy Lead

Logistics & Supply Chain Management

Updated on 9/12/2026

Deadline 9/16/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Mississauga, ON, Canada + 1 more

More locations: Sandwich, UK

Hybrid

Hybrid work arrangement; required office days are not specified.

Category
Operations & Logistics (1)
Required Skills
Supply Chain Management
Data Visualization
Forecasting
Quality Assurance (QA)

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • Knowledge of supply chain processes.
  • Expertise in clinical supply packaging, labelling, distribution, and logistics.
  • Project management skills for developing operational strategies and execution plans.
  • Ability to identify and mitigate operational risks.
  • Ability to work independently and influence stakeholders without a direct reporting relationship.
  • Ability to ensure quality and compliance with EHS, current Good Manufacturing Practice, Good Clinical Practice, import/export requirements, Quality Standards, and 21 CFR Part 11.
  • Ability to interpret clinical protocols and develop practical and efficient clinical-supply packaging designs.
  • Ability to coordinate and communicate multiple study packaging and labelling requirements across a global network of contract packaging organizations.
Responsibilities
  • Develop and implement mid- to long-term supply chain strategies for assigned programs and initiatives, including forecasts and packaging, labelling, distribution, and logistics events.
  • Monitor the effectiveness of operational strategies and partner with Clinical Supply Operations functional lines to ensure implementation and delivery of clinical supplies.
  • Represent Global Clinical Supply Operations on Clinical Supply Teams for assigned programs.
  • Ensure that overarching strategy and scenario planning for programs and protocols is developed with and shared among appropriate stakeholders.
  • Monitor and provide input to Global Clinical Supply Operations program and protocol dashboards as part of program management support.
  • Oversee delivery of clinical packaging, labelling, and trial-distribution activities to ensure clinical-study timelines are supported and met.
  • Ensure Global Clinical Supply Operations inspection readiness.
  • Participate in or lead strategic and continuous-improvement initiatives.
  • Provide program-level forecasts and special needs to vendors.
  • Provide packaging, labelling, and distribution/storage cost estimates.
  • Support integration activities when needed.
  • Serve as the Global Clinical Supply Operations point of contact with Supply Chain Leads and Clinical Research Pharmacists on operational strategy.
  • Coordinate fulfilment of customer requests and provide customer service.
  • Develop collaborative partnerships with stakeholders across partner lines and ensure quality and compliance through risk identification, mitigation planning, strategic planning, execution, and design input.
  • Assist Global Clinical Supply Operations leadership with strategic development of Clinical Supply Operations roles.
  • Evaluate current processes and recommend continuous improvements to packaging and distribution operating models.
  • Support fiscal accountability by refining project-specific costs.
  • Partner with Clinical Supply Operations functional-line leaders to develop and refine human-resource capacity analysis aligned with project needs and portfolio priorities.
  • Maintain required role training and compliance, enhance quality and compliance on a site and patient basis, and assess cross-functional impacts of procedure and process changes.
  • Interface with Global Clinical Supply and other Pfizer groups to provide guidance and resolve issues regarding clinical packaging and distribution activities.
  • Establish program-level integrated operational strategies with Clinical Supply Teams and contribute to country-feasibility and strategy discussions before protocol decisions.
  • Own timing and challenges related to country movements to meet project requirements.
  • Build working relationships with customers and partner leaders to facilitate communication about project priorities and issue resolution.
  • Triage issues and provide detailed updates to Clinical Supply Operations leadership.
  • Use project management skills to develop packaging and distribution/logistics planning and management tools, optimize operational strategy for patient continuity, and conduct project oversight and activity review.
  • Partner with Supply Chain Leads to review and interpret clinical protocols and develop packaging designs for clinical supplies.
  • Partner with Supply Chain Leads to generate and approve Clinical Packaging Requests.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.